Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10526MR)

This product GTTS-WQ10526MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Heterozygous familial hypercholesterolemia (HeFH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10526MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9856MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA K7153A
GTTS-WQ15705MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ4659MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986036
GTTS-WQ10925MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MABT5102A
GTTS-WQ15914MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XOMA 052
GTTS-WQ1227MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABR-217620
GTTS-WQ1768MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ10690MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LymphoStat-B
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW